Literature DB >> 10419035

Epidemiological research into nasopharyngeal carcinoma in the Chubu region of Japan.

H Takeshita1, M Furukawa, S Fujieda, H Shoujaku, T Ookura, M Sakaguchi, H Ito, H Mineta, T Harada, H Matsuura, H Saito.   

Abstract

Although patient death due to nasopharyngeal carcinoma (NPC) is increasing, few epidemiological analyses of NPC in Japan have been conducted since Sawaki's report in 1979. To determine the current incidence of NPC in Japan we examined NPC case in the Chubu area from 1986 to 1995. The leaders and reporting representatives of all otorhinolaryngological groups in the area were asked for their support of this epidemiological research. A total of 607 cases (445 male and 162 female NPC patients) were analyzed epidemiologically, histologically, serologically and clinically in this study. The incidence of NPC gradually increased with age. The mean age of the patients was 54.1 years. The age-standardized annual incidence in the Chubu region was 0.28 per 10(5) persons per year. The incidence in prefectures bordering Japan Sea (0.36) was significantly higher than that of prefectures facing the Pacific Ocean (0.21, P<0.05). On the basis of World Health Organization (WHO) histological criteria, 12%) of the cases were classified as WHO I, 54% as WHO II and 34% as WHO III. As for tumor origin, in 58% of the cases it originated posterosuperiorly, in 32% laterally and in 1% inferiorly. Tumor staging showed 4% to belong to stage I, 9% to stage II, 15% to stage III and 72% to stage IV. The positive rates of serum titers of the antibodies to Epstein Barr virus

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419035     DOI: 10.1016/s0385-8146(98)00080-7

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  6 in total

1.  Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma.

Authors:  Xi Zeng; Juanjuan Xiang; Minghua Wu; Wei Xiong; Hailin Tang; Min Deng; Xiayu Li; Qianjin Liao; Bo Su; Zhaohui Luo; Yanhong Zhou; Ming Zhou; Zhaoyang Zeng; Xiaoling Li; Shourong Shen; Cijun Shuai; Guiyuan Li; Jiasheng Fang; Shuping Peng
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

2.  Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in cantonese.

Authors:  Ya-Fei Xu; Wan-Li Liu; Ju-Qin Dong; Wen-Sheng Liu; Qi-Sheng Feng; Li-Zhen Chen; Yi-Xin Zeng; Mu-Sheng Zeng; Wei-Hua Jia
Journal:  BMC Med Genet       Date:  2010-11-11       Impact factor: 2.103

3.  The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types.

Authors:  A S Abdulamir; R R Hafidh; N Abdulmuhaimen; F Abubakar; K A Abbas
Journal:  BMC Public Health       Date:  2008-12-05       Impact factor: 3.295

4.  Incidence Trends and Geographical Distribution of Nasopharyngeal Carcinoma in Iran.

Authors:  Ali Safavi-Naini; Nasim Raad; Jahangir Ghorbani; Samira Chaibakhsh; Rashid Ramezani-Daryasar
Journal:  Iran J Cancer Prev       Date:  2015 Jan-Feb

5.  Third Epidemiological Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015.

Authors:  Masafumi Kanno; Norihiko Narita; Yasushi Fujimoto; Naohiro Wakisaka; Tomokazu Yoshizaki; Takeshi Kodaira; Chiyoko Makita; Yuichiro Sato; Keisuke Yamazaki; Takanori Wakaoka; Yuzo Shimode; Hiroyuki Tsuji; Ryosuke Kito; Hajime Ishinaga; Seiji Hosokawa; Hiromasa Takakura; Kunihiro Nishimura; Takuma Matoba; Shigeharu Fujieda
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

6.  Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma.

Authors:  Kina Kase; Satoru Kondo; Naohiro Wakisaka; Hirotomo Dochi; Harue Mizokami; Eiji Kobayashi; Makoto Kano; Takeshi Komori; Nobuyuki Hirai; Takayoshi Ueno; Yosuke Nakanishi; Miyako Hatano; Kazuhira Endo; Makiko Moriyama-Kita; Hisashi Sugimoto; Tomokazu Yoshizaki
Journal:  Microorganisms       Date:  2021-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.